Open AccessRecombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
Author(s) -
Ansari Amir M.,
Khorasanchi Adam,
Faghihimehr Armaghan,
Toor Amir
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4788
Subject(s) - medicine , recombinant factor viia , coagulopathy , intracranial bleeding , refractory (planetary science) , hematoma , recombinant dna , gastrointestinal bleeding , multiple myeloma , subdural hemorrhage , surgery , anticoagulant , gene , biochemistry , chemistry , physics , astrobiology
Abstract Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA‐approved agent for management of bleeding in hemophilia patients with inhibitors. Use of recombinant FVIIa has also been used as a last resort in various clinical settings such as trauma, alveolar hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage for control of bleeding with variable outcomes. This paper presents a case of recombinant FVIIa administration in a patient with multiple myeloma and profound transfusion refractory thrombocytopenia suffering from traumatic subdural hematoma.